FDA approves overdose-reversing Narcan for over-the-counter sale
Comments on how OTC naloxone isn’t enough to address issues with access.
FDA approves overdose-reversing Narcan for over-the-counter sale
Comments on how OTC naloxone isn’t enough to address issues with access.
Jonathan JK Stoltman, PhD is Director of the Opioid Policy Institute. They have been an addiction scientist since 2013. Their work has appeared in leading academic journals and in the media.
All articles